Crohn’s & Colitis Congress™

Sessions (24)

15 - DISRUPTION OF FOXP3-EZH2 INTERACTION BY GENETIC MUTATION OR SIGNALING-INDUCED INACTIVATION REPRESENTS A NOVEL PATHOBIOLOGICAL MECHANISM IN INFLAMMATORY BOWEL DISEASE (Room Pinyon 1/2)

20 Jan 18
8:00 AM - 8:07 AM

Question and Answer (Room Pinyon 1/2)

20 Jan 18
9:30 AM - 9:40 AM

20 - ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT (Room Pinyon 4/5)

20 Jan 18
8:00 AM - 8:07 AM

Question and Answer (Room Pinyon 4/5)

20 Jan 18
11:50 AM - 12:00 PM

Basic Quick Shots Breakout (Room Pinyon 1/2)

20 Jan 18
8:00 AM - 8:35 AM

Clincial Quick Shots Breakout (Room Pinyon 4/5)

20 Jan 18
8:00 AM - 8:35 AM

16 - GENETIC ANALYSIS IDENTIFIED NOVEL LOCI ASSOCIATED WITH IBD (Room Pinyon 1/2)

20 Jan 18
8:07 AM - 8:14 AM

21 - WHAT IS THE MOST COST-EFFECTIVE POSITION OF VEDOLIZUMAB IN THE CURRENT TREATMENT ALGORITHM OF ULCERATIVE COLITIS? (Room Pinyon 4/5)

20 Jan 18
8:07 AM - 8:14 AM

17 - SINGLE-CELL SEQUENCING OF CREEPING FAT IN CROHN’S DISEASE REVEALS DISTINCT IMMUNE CLUSTERS AND CELLULAR RESTRUCTURING IN THE PRESENCE OF LIVE BACTERIA AND FUNGI (Room Pinyon 1/2)

20 Jan 18
8:14 AM - 8:21 AM

22 - PERSISTENT OPIOID USE AND HEALTHCARE UTILIZATION AMONG ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES (Room Pinyon 4/5)

20 Jan 18
8:14 AM - 8:21 AM

18 - MYELOID VITAMIN D RECEPTOR SIGNALING REGULATES PANETH CELL FUNCTION AND INTESTINAL HOMEOSTASIS

20 Jan 18
8:21 AM - 8:28 AM

23 - EMERGENT COLECTOMY RATES DECREASED WHILE ELECTIVE IPAA RATES WERE STABLE OVER TIME: A NATIONWIDE INPATIENT SAMPLE STUDY (Room Pinyon 4/5)

20 Jan 18
8:21 AM - 8:28 AM

24 - HIGHER BODY MASS INDEX IS ASSOCIATED WITH INCREASED RISK OF TREATMENT FAILURE AND SURGERY IN BIOLOGIC-TREATED PATIENTS WITH ULCERATIVE COLITIS (Room Pinyon 4/5)

20 Jan 18
8:28 AM - 8:35 AM

Clinical Challenges You Face Every Day (Room Pinyon 4/5)

20 Jan 18
8:35 AM - 9:40 AM

Translational Research Breakout (Room Pinyon 1/2)

20 Jan 18
8:35 AM - 9:40 AM

Engineering the Gut Environment for the Treatment of IBD (Diet and Microbiome) as Short-to-Intermediate Deliverable (Room Pinyon 1/2)

20 Jan 18
8:40 AM - 8:55 AM

Advancing Findings in Immunology (Room Pinyon 1/2)

20 Jan 18
8:55 AM - 9:10 AM

25 - MUTATIONS IN STXBP3 CONTRIBUTE TO VERY EARLY ONSET OF IBD, IMMUNODEFICIENCY AND HEARING LOSS (Room Pinyon 1/2)

20 Jan 18
9:10 AM - 9:20 AM

26 - A HUMAN-ASSOCIATED FECAL TRANSPLANTATION MOUSE MODEL TO STUDY THE FUNCTIONALITY OF THE GUT MICROBIOME (Room Pinyon 1/2)

20 Jan 18
9:20 AM - 9:30 AM

Keynote Research Presentation: Advancing Findings in Epithelial Biology and Immune/Epithelial Interactions to Improve Mucosal Healing (Room Pinyon 4/5)

20 Jan 18
10:10 AM - 10:30 AM

27 - CLINICAL AND GENOMIC CORRELATES OF NEUTROPHIL GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR SIGNALING IN PEDIATRIC CROHN DISEASE (Room Pinyon 4/5)

20 Jan 18
10:30 AM - 10:40 AM

Keynote Clinical Presentation: Treating the Refractory Patient and the Rising Bar for IBD Outcomes (Room Pinyon 4/5)

20 Jan 18
10:40 AM - 11:00 AM

28 - CHARACTERISTICS AND OUTCOMES OF PROSPECTIVELY REPORTED PREGNANCIES EXPOSED TO CERTOLIZUMAB PEGOL FROM A SAFETY DATABASE (Room Pinyon 4/5)

20 Jan 18
11:00 AM - 11:10 AM

Basic Theme (Room Pinyon 4/5)

20 Jan 18
11:10 AM - 11:30 AM

Highlight: One Basic Research Theme, One Clinical Research Theme in 2017 (Room Pinyon 4/5)

20 Jan 18
11:10 AM - 11:50 AM

Clinical Theme (Room Pinyon 4/5)

20 Jan 18
11:30 AM - 11:50 AM